FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to PEGylated analogs of growth hormone release hormone (GHRH), and can be used in medicine for therapy and diagnosis of a condition associated with growth hormone deficiency. Proposed is an analog of GHRH of the formula X1-X2-Asp-Ala-lle-Phe-Thr-X8-X9-Tyr-X11-X12-Val-Leu-X15-Gln-Leu-X18-Ala-X20-X21-X22-Leu-X24-X25-X26-X27-X28-X29-X30, including Cys at Position X9, conjugated to a PEG polymer with a molecular weight of less than or equal to 5 kDa. The analog can also be PEGylated at Positions 22, 24 and 28.
EFFECT: invention provides a GHRH analog with enhanced biological activity.
20 cl, 4 tbl, 3 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| USE OF OPTIONS OF NATRIURETIC PEPTIDE OF TYPE C FOR TREATMENT OF OSTEOARTHRITIS | 2016 |
|
RU2759679C2 |
| CNP PRODRUGS | 2016 |
|
RU2824988C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| SWINE G-CSF VARIANTS AND APPLICATION THEREOF | 2018 |
|
RU2823074C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| INTERLEUKIN 10 CONJUGATES AND APPLICATIONS THEREOF | 2020 |
|
RU2829811C1 |
